Nanotechnology Community

 View Only
Back to discussions
Expand all | Collapse all

"Beyond Lipid Nanoparticles: Navigating the Complex Landscape of Lipid-Based Delivery Systems"

  • 1.  "Beyond Lipid Nanoparticles: Navigating the Complex Landscape of Lipid-Based Delivery Systems"

    Posted 01-14-2025 23:12

    Hello All,

    Since the COVID-19 pandemic and the widespread use of lipid nanoparticles (LNPs), there has been considerable confusion surrounding the terminology. While liposomes are a well-known type of lipid-based particle and some are nano-sized, is it appropriate to classify them as LNPs? Additionally, many other delivery systems (e.g., emulsions) and diagnostics utilize both natural and synthetic lipids, with compositions, architectures, and performances that differ significantly from LNPs.


    How do you think the misuse of the term 'lipid nanoparticle' affects the development and public perception of these advanced drug delivery systems? As enthusiasts in nanotechnology development and application, what steps can we take to ensure accurate terminology in scientific communication?



    ------------------------------
    Robert D. Arnold, Ph.D. "Rusty"
    Professor, Director of Research Development & Support
    Department of Drug Discovery & Development
    Auburn University, Harrison College of Pharmacy
    Auburn, AL 36849 U.S.A.
    Email: [email protected]
    Office: (334) 844-8434

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------


  • 2.  RE: "Beyond Lipid Nanoparticles: Navigating the Complex Landscape of Lipid-Based Delivery Systems"

    Community Leadership
    Posted 01-16-2025 12:57

    Hi Rusty:

      I agree LNPs are is misused a lot as they are not really LIPOSOMES or other lipid based emulsions or particles.  They are made in a very specific manner and have a specialized application.  I recently tried to explain the difference in a Prologue I gave at the 2024 NBC on "Drug Delivery Systems: New modalities, Opportunities, and Challenges for Lipid based Drug Delivery Systems for biopharmaceuticals." that could be shared in your community.

    Regards,

    Rajiv Nayar



    ------------------------------
    Rajiv Nayar Ph.D.
    President
    HTD Biosystems Inc.
    Livermore CA
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------

    Original Message